Skip to Main Content
Back to News

Insider Sale: EVP of $BMY Sells 56,000 Shares

Automated

David V Elkins, the EVP of $BMY, sold 56,000 shares of the company on 09-02-2025 for an estimated $2,650,480. We received data on the trade from a recent SEC filing. This was a sale of approximately 25.1% of their shares of this class of stock. Following this trade, they now own 167,379 shares of this class of $BMY stock.

$BMY Insider Trading Activity

BMY Insider Trades

$BMY insiders have traded $BMY stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.

Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:

  • DAVID V ELKINS (EVP, Chief Financial Officer) sold 56,000 shares for an estimated $2,650,480
  • SAMIT HIRAWAT (EVP,Chief Med.Offr.,Drug Dev.) purchased 4,250 shares for an estimated $202,215
  • BARTIE WENDY SHORT (EVP, Corporate Affairs) sold 378 shares for an estimated $16,718
  • BENJAMIN HICKEY (President, RayzeBio Org.) sold 97 shares for an estimated $3,701

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BMY Hedge Fund Activity

We have seen 942 institutional investors add shares of $BMY stock to their portfolio, and 1,471 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BMY Congressional Stock Trading

Members of Congress have traded $BMY stock 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$BMY Analyst Ratings

Wall Street analysts have issued reports on $BMY in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

  • Jefferies issued a "Buy" rating on 04/23/2025
  • Piper Sandler issued a "Overweight" rating on 04/22/2025

To track analyst ratings and price targets for $BMY, check out Quiver Quantitative's $BMY forecast page.

$BMY Price Targets

Multiple analysts have issued price targets for $BMY recently. We have seen 8 analysts offer price targets for $BMY in the last 6 months, with a median target of $54.5.

Here are some recent targets:

  • Andrew Baum from Citigroup set a target price of $47.0 on 08/01/2025
  • Terence Flynn from Morgan Stanley set a target price of $34.0 on 07/10/2025
  • Mohit Bansal from Wells Fargo set a target price of $53.0 on 04/28/2025
  • Carter Gould from Cantor Fitzgerald set a target price of $55.0 on 04/23/2025
  • Akash Tewari from Jefferies set a target price of $68.0 on 04/23/2025
  • David Amsellem from Piper Sandler set a target price of $65.0 on 04/22/2025
  • Trung Huynh from UBS set a target price of $54.0 on 04/11/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles